Background This study evaluates the cost-effectiveness of pertuzumab with trastuzumab
biosimilar and docetaxel as initial treatment for HER2-positive metastatic breast cancer …

Background: This study aimed to analyze the cost effectiveness of camrelizumab in the
second-line treatment of advanced or metastatic esophageal squamous cell carcinoma in …

Purpose To summarize current understanding of the efficacy, role, and cost-effectiveness of
the available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), and …

Background Toripalimab is an immune checkpoint inhibitor (ICI) against programmed death
ligand 1 (PD-L1). It has been approved for advanced esophageal squamous cell carcinoma …

Objective: To assess the cost-effectiveness of pembrolizumab monotherapy compared with
standard chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) …

Objective Non-small cell lung cancer (NSCLC) accounts for 80–90% of all lung cancer
cases and is usually associated with a poor prognosis. However, targeted therapy with first …

Objective To evaluate the cost-effectiveness of olaparib as a maintenance treatment versus
routine surveillance (RS) in patients with BRCA mutated (BRCAm) advanced ovarian cancer …

Objective The purpose of this study was to evaluate the cost-effectiveness of the combined
use of afatinib and epidermal growth factor receptor (EGFR) testing versus gemcitabine …

Background Lung cancer is imposing significant pressure on the national health insurance
system worldwide, especially under the COVID-19 pandemic. However, the cost …

Aim: To evaluate the cost-utility of gefitinib and afatinib as first-line EGFR-mutated non-small-
cell lung cancer treatments from the Chinese healthcare system perspective. Materials & …